Ethics & Compliance

Veloxis Pharmaceuticals, Inc. (“Veloxis” or the “Company”) has established an ethics and compliance program that reflects our commitment to the Veloxis mission, core values, and to conducting business in compliance with the laws, regulations, guidance, and industry standards that govern our organization.

The Veloxis Chief Ethics and Compliance Officer and the Ethics and Compliance Team are responsible for overseeing the ethics and compliance program.

Please access an overview of our ethics and compliance program here.

If you have questions regarding our ethics and compliance program, please email us at compliance@veloxis.com.

Ethics and Compliance Helpline

Veloxis is committed to essential principles of good corporate conduct and integrity across all its activities. If Veloxis becomes aware of violations of law or Veloxis policy, we will investigate the matter and, where appropriate, take disciplinary action and implement corrective measures to prevent future violations.

We have set up an external compliance helpline system called the Veloxis Anonymous Compliance Reporting Helpline—operated by an independent, certified third-party vendor for our employees and related parties to report potential violations of laws or Company guidelines.

To anonymously report a suspected violation of law or Company policy to the Veloxis Anonymous Compliance Reporting Helpline:

Call: 1-833-214-6429 (English) or 1-800-216-1288 (Spanish);

Email: reports@lighthouse-services.com (please include “Veloxis” in subject line); or

Web Portal: https://www.lighthouse-services.com/veloxis

Code of Conduct

The Veloxis Code of Conduct has been adopted by the Veloxis Board of Directors to aid its directors, officers, employees, and colleagues with making ethical and legal decisions when conducting business and performing their day-to-day duties.

Access the Veloxis Code of Conduct.

California Declaration of Compliance

Please access the Veloxis declaration of compliance with California Health and Safety Code §§ 119400-119402.

Colorado

In accordance with the Colorado Wholesale Acquisition Cost Disclosure Law (Colorado Revised Statutes Section 12-42.5-308), Veloxis is disclosing to authorized prescribers of prescription drugs in Colorado the wholesale acquisition cost (WAC) pricing information of ENVARSUS XR^® (tacrolimus extended-release tablets).

Connecticut

In accordance with Connecticut Public Act No. 23-171, Veloxis is disclosing to prescribing practitioners and pharmacists in Connecticut certain required wholesale acquisition cost (WAC) pricing information of ENVARSUS XR^® (tacrolimus extended-release tablets).